Back to News
Dec 29, 2025 12:10 PM

Novo Nordisk Halves Wegovy Prices In China Ahead Of Generic Threat

Novo Nordisk A/S (NYSE:NVO) has reportedly slashed list prices for its obesity drug Wegovy by about 50% in parts of China, signaling a defensive move ahead of rising generic competition.

Citing local print media, Bloomberg noted on Monday that prices for the two highest Wegovy doses were reduced to 987.48 yuan ($141) and 1,284.36 yuan in provinces including Yunnan and Sichuan, based on government drug-procurement documents.

Novo said the cuts are intended to ease patient costs and support treatment adherence.

Also Read: Food Companies Rethink Menus For GLP-1 Users As Wegovy Weight Loss Pill Gets Approval

Prices on JD.com’s (NASDAQ:JD) online pharmacy have also been lowered, allowing ...